About admin

This author has not yet written his bio.
Meanwhile let's just say that we are proud admin contributed with 18 entries.

Entries by admin

Treventis Diagnostics highlighted in recent press articles

The Treventis diagnostics program, headed by neurologist and medicinal chemist Dr. Sultan Darvesh, was recently featured in two news articles:



[…] Read more

Servier and Treventis begin strategic research partnership in neurodegenerative diseases

Paris (France) and Toronto (Canada), 4 January 2018 – Servier and Treventis announce strategic research partnership in targeting misfolded proteins implicated in neurodegenerative diseases. The collaboration covers a large drug discovery program targeting both tau and amyloïde-β (Aβ), two key proteins involved in Alzheimer’s disease. This therapeutic strategy aims to provide patients with a drug that slows the progression of pathology in the brain, thereby minimizing functional decline through a disease-modifying mechanism. 

Servier and Treventis will jointly develop compounds that act as inhibitors of tau and Ab oligomer formation, identified by Treventis’ Common Conformational Morphology (CCM) platform technology. The collaboration […] Read more

TREVENTIS becomes a resident of JLABS @ Toronto

May 11, 2017 – Toronto, ON – TREVENTIS has become a resident of JLABS @ Toronto.

JLABS@ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

For further details, please see the Johnson […] Read more

Treventis AD diagnostic tested in mice

Research presented this year at the Alzheimer’s Association International Conference® (AAIC®), the world’s largest forum for the dementia research community, in Toronto, Canada, included SPECT data on Treventis Diagnostics’ tool compound TRV6001 collected on a novel compact SPECT instrument manufactured by Cubresa.  Further details can be found in the Cubresa press release.

[…] Read more

Treventis Corporation presents research from its anti-oligomer therapeutic program at AAIC

July 22, 2016 – Toronto, ON – Treventis Corporation presented research from its anti-oligomer therapeutic program at the Alzheimer’s Association International Conference in Toronto, showcasing the advances it is making in profiling (in vitro and in vivo) compounds that affect the earliest phases of beta-amyloid and tau oligomerization and demonstrating this unique mechanism of action using experimental techniques.

Mark Reed, Senior VP of Research at TREVENTIS, presented a poster entitled “Discovery of small molecule dual inhibitors of both beta-amyloid and tau oligomerization”, on behalf of the TREVENTIS therapeutics division.  This poster summarized the progress made towards in vitro and in vivo profiling […] Read more

Treventis Diagnostics wins I-3 Life Sciences sector award

Treventis Diagnostics’ program in PET/SPECT tracers for Alzheimer’s disease caught the attention of the I-3 Technology Start-up Competition sponsored by Innovacorp.  The company received a $25,000 award as the best life sciences start-up operating within Nova Scotia.  This was a highly competitive competition and the company was pleased to be recognized for its work.

For more information, please see the Innovacorp I-3 press release.

[…] Read more

TREVENTIS Corporation therapeutic compound demonstrates significant reduction in both amyloid beta and tau toxic aggregates in animal models of Alzheimer’s disease

July 20, 2015 – Philadelphia, PA – Treventis Corporation announced today that the Company’s compound TRV 101 has successfully demonstrated significant reduction in the toxic aggregates/ oligomers of both amyloid beta and tau protein in multiple transgenic mouse models of Alzheimer’s Disease (AD).  Using industry standard mouse models of amyloid beta (APP/PS1) and tau (rTg4510), a reduction of ~ 30-40% in both tau and amyloid beta oligomers was observed in the brain following oral administration TRV 101 over a 3-7 day period.

>“Toxic oligomers or aggregates of beta-amyloid and tau protein are known to have synergistic and pathogenic roles in the progression […] Read more

Treventis discoveries recently featured on NPR, other media

July 19 , 2015 – Philadelphia, PA – A recent story on NPR featured the presentation of new research by Treventis at AAIC in Washington D.C. this week.

“Our ultimate goal is to discover a pill that can be taken once a day that could either stop or slow Alzheimer’s disease,” says Marcia Taylor, the company’s director of biological research. Treventis hopes to do that with a drug that prevents the build-up of two toxic proteins.

Read the whole article describing our work toward a therapy for Alzheimer’s.

These findings were also featured in other media outlets as well, with more to come:

The […] Read more

Treventis scientists present findings at ADPD Conference in Nice

Nice – Treventis scientists today presented their poster “DESIGN AND OPTIMIZATION OF SMALL MOLECULE MISFOLDING INHIBITORS TARGETING BOTH BETA-AMYLOID AND TAU” at the Alzheimer’s and Parkinson’s disease congress in Nice, France.

The research presented described further progress in the Wellcome Trust-funded program toward small molecule inhibitors of both beta-amyloid and tau oligomerization in Alzheimer’s disease.  Compounds in the TRV1XX series were tested in various assays of in vitro target engagement as well as in vivo ADME/PK and chronic efficacy models.  These lead compounds are being further optimized for potential selection as clinical candidates.

The poster can be read here: MTaylorADPD2015

[…] Read more

TREVENTIS Corporation Scientific Founder for Diagnostics, Sultan Darvesh, MD, Named Sobey Chair in Alzheimer’s Disease Research

Halifax, Nova Scotia, Canada – TREVENTIS Corporation announced today that one of the Company’s scientific founders, Sultan Darvesh, MD, PhD, was named as the Sobey Chair in Alzheimer’s disease research at Dalhousie University in Halifax, Nova Scotia, Canada. This chair has been established as the result of a $2 million donation to the Dalhousie Medical Research Foundation (DMRF) from the Sobey Foundation. It will fund the DMRF Irene MacDonald Sobey Endowed Chair in Curative Approaches to Alzheimer’s Disease. The Sobey Foundation is funded by the Sobey family, who operate many diverse companies throughout Canada including chain grocery […] Read more